Eplerenone in HIV Associated Abdominal Fat Accumulation
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle
modification to affect sugar metabolism, body fat distribution, and cardiovascular health in
HIV-infected individuals. In non-HIV-infected individuals, recent data has shown that
aldosterone, a hormone that regulates salt and water balance, is increased in association
with increased belly fat and decreased insulin sensitivity. In HIV-infected individuals,
aldosterone appears to be higher in individuals with increased belly fat, and increased
aldosterone appears to be strongly associated with impaired sugar metabolism. In this study,
the investigators will test the effects of eplerenone, which is a medication that blocks the
actions of aldosterone, along with lifestyle modification. The investigators hypothesize that
eplerenone may improve sugar metabolism, improve markers of cardiovascular health, and reduce
fat accumulation in liver and muscle.